Porphyria (AIP - Acute Attack) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Porphyria (AIP - Acute Attack)
Acute Intermittent Porphyria (AIP) is a rare genetic disorder that can trigger severe, life-threatening acute attacks. These episodes demand prompt and often costly medical intervention. TheDrugClub is dedicated to helping individuals and families facing AIP by significantly reducing their prescription expenses, ensuring essential treatments are more accessible and affordable.
Acute Intermittent Porphyria (AIP) is a rare, inherited metabolic disorder characterized by defects in the heme biosynthesis pathway. Heme is a vital component of hemoglobin, which carries oxygen in the blood. When this pathway malfunctions, toxic byproducts called porphyrin precursors accumulate in the body, leading to acute attacks. These attacks can be triggered by various factors, including certain medications, alcohol, stress, fasting, hormonal changes, and infections.
Symptoms of an AIP acute attack can be debilitating and wide-ranging. They often include severe abdominal pain, nausea, vomiting, constipation, and muscle weakness. Neurological symptoms are also common, manifesting as anxiety, confusion, hallucinations, seizures, and, in severe cases, paralysis. If left untreated, an acute attack can be life-threatening, making timely diagnosis and intervention crucial. Diagnosis typically involves urine tests to detect elevated levels of porphyrin precursors during an attack.
Treatment for an AIP acute attack focuses on halting the overproduction of porphyrin precursors and managing symptoms. The primary treatment during an acute attack is intravenous hemin (e.g., Panhematin, Cinvanti), which helps suppress the heme pathway. Supportive care includes pain management, anti-nausea medications, and intravenous fluids for hydration. For individuals experiencing frequent or severe recurrent attacks, newer therapies like givosiran (Givlaari), an RNA interference therapeutic, can help reduce the frequency and severity of attacks. These specialized medications, while essential, can be incredibly expensive, posing a significant financial burden on patients and their families.
This is where TheDrugClub steps in to help. For a monthly membership fee
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.